Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …

Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …

Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …

In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with
metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 …

Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …